|
|
| |
Dacryodes edulis (G. Don) H.J. Lam: A Review on its Medicinal, Phytochemical and Economical Properties |
|
K.K. Ajibesin |
Abstract:
Dacryodes edulis is a dioecious, shade loving, evergreen tree, indigenous to the Gulf of Guinea and widely cultivated in other tropical parts of Africa for its fruit. The edible fruit to which the plant owes its principal values is a rich source of nutrients such as lipids, vitamins and protein. The fruit yields a high content of fixed and essential oils. The fruits are highly consumed and traded locally and internationally, conferring enormous economic value on the plant. The plant has long been used in the traditional medicine of some African countries to treat various ailments such as wound, skin diseases, dysentery and fever. The extracts and secondary metabolites have been found to show biological activities such as antimicrobial, antioxidant and anti sickle cell anemia. A wide range of chemical constituents such as terpenes, flavonoids, tannins, alkaloids and saponins have been isolated from the plant. This review provides a comprehensive detail of the plant’s ethnomedicinal uses, biological effects, chemical constituents and economic property as a medicinal plant.
|
|
|
PDF
Fulltext
XML
References
Citation
Report Citation
|
|
|
|
| RELATED ARTICLES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
How to cite this article:
K.K. Ajibesin , 2011. Dacryodes edulis (G. Don) H.J. Lam: A Review on its Medicinal, Phytochemical and Economical Properties. Research Journal of Medicinal Plants, 5: 32-41.
URL: https://scialert.net/abstract/?doi=rjmp.2011.32.41
|
|
|
| COMMENTS |
16 October, 2012
Tom K.Thomas:
Very much informative,iam interested to know which part of the tree is yoused to treat sickle cell anemiea,fruit,Bark, resein. |
|
19 August, 2014
Okonta Ndubuisi Raymond:
Very information, am working on an undergraduate project that has something to do with the medicinal potentials of the seed of this plant "Dacryodes Edulis" and its phytochemical compositions. I would appreciate a reply to my email. |
|
|
|
|
| COMMENT ON THIS PAPER |
|
|
